Key insights
- 10x Genomics CEO sold $122k in stock, coinciding with a significant stock run-up and mixed analyst sentiment. While William Blair upgraded TXG citing AI-driven drug discovery potential and strong operational performance, Wolfe Research and ARK Invest expressed concerns. Wolfe noted potential AI impact on spatialomics demand, and ARK's substantial share sale raises questions about institutional confidence. The CEO's sale, though under a pre-planned
Serge Saxonov, Chief Executive Officer of 10x Genomics NASDAQ:TXG, sold 5,000 shares of Class A Common Stock on April 14, 2026. The shares were sold at prices ranging from $24.49 to $24.70, realizing a total of $122,784. The sale comes as the stock trades near its 52-week high of $25.69, following a remarkable 216% gain over the past year.
The transaction was executed under a Rule 10b5-1 trading plan adopted by Saxonov on November 29, 2025. Following the sale, Saxonov directly owns 1,167,273 shares of 10x Genomics.
Saxonov also has indirect ownership of 27 shares held by the Andromeda Trust, 213,250 shares held by the Y/S Descendants’ Trust, and 71,644 shares held by the Y/S Pot Trust, for which he serves as trustee.According to InvestingPro analysis, the stock appears overvalued at current levels. Investors seeking deeper insights can access a comprehensive Pro Research Report covering TXG and 1,400+ other US equities.
In other recent news, 10X Genomics has been upgraded by William Blair to an Outperform rating, highlighting the company’s role in AI-driven drug discovery. William Blair noted that 10X Genomics has achieved five consecutive top-line beats and has reached adjusted EBITDA breakeven, with single cell volumes experiencing double-digit growth for the fourth consecutive quarter. In a strategic partnership, Bioptimus launched the Spatial Tissue Embedding Learning Atlas (STELA) with 10X Genomics and Broad Clinical Labs, aiming to profile up to 100,000 patient tissue specimens globally. This represents a significant scale increase over existing spatial biology atlases. Meanwhile, Wolfe Research commented on a sell-off in spatialomics stocks, including 10X Genomics, following concerns about AI technology potentially reducing demand for spatial proteomics. Additionally, ARK Invest sold over 473,000 shares of 10X Genomics, raising concerns about institutional investor confidence in genomics toolmakers. Lastly, Stifel raised its price target for 10X Genomics to $25, maintaining a Buy rating due to the solid adoption of the company’s new Flex Apex product.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates TXG every month against thousands of alternatives using 100+ financial metrics.It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could TXG be next—or is there a better opportunity in the same space?Don't wait to find out.